Christina T. Loguidice


Study Suggests Panurothelial Carcinoma Warrants More Aggressive Surgical Treatment

A study published in Scientific Reports by researchers from China indicates panurothelial carcinoma (panUCC) has a high risk of recurring, progressing, and disseminating after conservative surgery, leading to poor outcomes.

Christine Lehmann


Quantifying the Benefits of Precision Oncology

Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.

Christine Lehmann, MA


Immunotherapy and TKI Combinations Are Emerging as Standard of Care in Advanced RCC

The results of several studies presented at the 2019 Genitourinary Cancers Symposium confirmed that the combination of PD-1/PD-L1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway was superior to VEGF inhibitors alone in patients with clear cell renal cell carcinoma, which accounts for about 70% of patients with kidney cancer.

Christine M. Lovly, MD, PhD


Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.

Christine Tran, MS


The Emerging Role of Mobile Health in Oncology

This article offers an overview of mobile health technology as it relates to a participatory care model and shared decision making.

Christoph Roellig, MD


Dr. Roellig on FLT3 ITD/NPM1 Mutation Status for Patients With AML

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Christophe Mariette, MD, PhD


The Impact of Age, Comorbidity on Postoperative Outcomes in Esophageal and Gastric Cancer

Christophe Mariette, MD, PhD, surgical oncologist and professor of surgery, University Hospital of Lille in France, discusses a nationwide study investigating the impact of age and comorbidities on postoperative mortality after esophageal and gastric cancer surgery.

Christopher E. Barbieri, MD, PhD


The Role of PARP Inhibitors in Prostate Cancer

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the role of PARP inhibitors in castration-resistant prostate cancer.

Christopher Filson, MD


MR-US Fusion Biopsy for Detecting High-Grade Prostate Cancer

Christopher Filson, MD, urology, UCLA Medical Center, discusses a study that used a MR-US fusion biopsy in 1000 men as a method to diagnose high-grade prostate cancer.

Christopher Heery, MD


The Potential Benefits of Combination Therapy for Patients with GI Cancers

Christopher Heery, MD, medical oncologist, National Cancer Institute, discusses the potential underlying benefits of combination therapy in the treatment of patients with gastrointestinal (GI) cancers.

Christopher J. Hoimes, DO


Addressing an Unmet Medical Need in Urothelial Carcinoma

Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.

Christopher R. Cogle, MD


Expert Explains the Greatest Challenge in Treating Patients With MDS and AML

Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.

Christopher R. Flowers, MD


Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients

Christopher Sweeney, MBBS


Expert Discusses Safety Profile from the ENZAMET Trial

Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events associated with adding enzalutamide or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET trial.<br /> &nbsp;

Christopher Twelves, MD


Dr. Christopher Twelves on the Rising Issue of Metastatic Breast Cancer

Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed.

Christopher Y. Park, MD


Biggest Challenges in MDS

Christopher Y. Park, MD, PhD, hematopathologist, Memorial Sloan Kettering Cancer Center, discusses some of the biggest challenges in myelodysplastic syndromes (MDS).

Chung-Han Lee, MD, PhD


Transforming Treatments in Non-Clear Cell Renal Cell Carcinoma

In the third article of this series, Chung-Han Lee, MD, PhD, gives an overview of non-clear cell renal cell carcinoma, discusses key clinical trial data, and looks to the future of renal cell carcinoma treatment.

Claire Harrison, MD


Dr. Claire Harrison on the Benefits of Ruxolitinib in Advanced Myelofibrosis

Claire Harrison, MD, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.

Claudine Isaacs, MD


Challenges in the Field of Hereditary Breast Cancer

Claudine Isaacs, MD, professor, medical Director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses some of the challenges physicians are facing in the field of hereditary breast cancer.

Clifford A. Hudis, MD


Dose-Dense Chemotherapy for Breast Cancer

Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.

Clifford A. Hudis, MD, FACP


Dr. Clifford A. Hudis on the Importance of In-Breast Response Rates in Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.

Clifford Hudis, MD


The Relationship Between Obesity and Breast Cancer

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology, discusses the significance of the relationship between breast cancer and obesity.

Colin G. Evans, PhD


Preventing and Treating Bone Metastases in mCRPC

Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Colin Weekes, MD, PhD


Dr. Colin Weekes on Molecular Phenotyping in Pancreatic Cancer

Colin Weekes, MD, PhD, associate professor, Department of Medicine and Medical Oncology, University of Colorado, on molecular phenotyping in pancreatic cancer patients.

Constantine S. Tam, MD


Ibrutinib Plus Venetoclax Is a Potential Second-line Regimen in MCL

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.